Harpoon Mitral Valve Repair System Found Safe and Effective
News | Heart Valve Technology | November 07, 2017

November 7, 2017 — A new study has found that a pioneering device to...

Acutus dipole density EP mapping for ablation procedures.

The FDA recently cleared high-speed Acutus Medical's AcQMap High Resolution image and mapping system and the AcQMap 3-D Imaging and Mapping Catheter.  detects and displays both standard voltage-based and higher resolution dipole density (charge-source) maps. The system combines ultrasound anatomy construction with an ability to map the electrical-conduction of each heartbeat to identify complex arrhythmias across the entire atrial chamber. Following each ablation treatment, the heart can be re-mapped in seconds to continually visualize any changes from the prior mapping.

 

 

Feature | Atrial Fibrillation | November 07, 2017

November 7, 2017 — Here is an aggregated list of articles detailing the latest clinical data and new device...

HREVS study principal investigator Vladimir Ganyukov, M.D., Ph.D., head of interventional cardiology, State Scientific Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia, at TCT 2017.

Study principal investigator Vladimir Ganyukov, M.D., Ph.D., head of interventional cardiology, State Scientific Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia, explaining the HREVS trial results at TCT 2017.

News | November 06, 2017 | Dave Fornell

November 6, 2017 — In the Hybrid REvascularization Versus Standards (HREVS) study that evaluated three different...

Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017

November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study,...

TeraRecon Introduces 175-Plus New Features in iNtuition 4.4.13
Technology | Advanced Visualization | November 06, 2017

November 6, 2017 — TeraRecton announced the launch of version 4.4.13 of its iNtuition...

Mitralign's Trialign system is used for transcatheter repair of tricuspid valve regurgitation. TCT 2017
News | Heart Valve Technology | November 06, 2017

November 6, 2017 — One year follow-up data from the SCOUT I Early Feasibility Study for the Mitralign Trialign...

Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents
News | Antiplatelet and Anticoagulation Therapies | November 06, 2017

November 6, 2017 —  The first trial to evaluate the safety of...

FAME2 cost effectiveness of FFR guided PCI vs. medical therapy alone. TCT 2017

FAME2 cost effectiveness of FFR guided PCI vs. medical therapy alone.

News | FFR Technologies | November 06, 2017

November 6, 2017 — Three-year data from the FAME 2 study show patients with coronary artery disease who underwent a...

Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting | November 06, 2017

November 6, 2017 — Elderly patients undergoing...

HeartFlow's FFR-CT (FFRct) analysis software can create a virtual FFR to assess coronary artery disease.

HeartFlow's FFR-CT analysis software uses a computed tomography scan and supercomputing fluid dynamics software to create a noninvasive, virtual FFR map of the entire coronary artery tree to determine the flow-limiting severity of ant lesions. 

News | Cardiac Imaging | November 06, 2017

November 6, 2017 – The Centers for Medicare & Medicaid Services (CMS) has finalized a New Technology Ambulatory...

Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting | November 03, 2017

November 3, 2017 — Biotronik's Orsiro...

Statins Attributed With 10-Year Cholesterol Drop for Malaysian Heart Attack Patients
News | Antiplatelet and Anticoagulation Therapies | November 03, 2017

November 3, 2017 — A ten-year decline in the blood cholesterol of heart attack patients in Malaysia suggests...

The Abbott/St. Jude Confirm RX implantable cardiac monitor (ICM) is the first ICM that is compatible with patients' smartphones to eliminate the need for a bedside base unit monitor to transfer data to physicians. Its FDA clearance was in October 2017.

The Abbott/St. Jude Confirm RX implantable cardiac monitor (ICM) is the first ICM that is compatible with patients' smartphones to eliminate the need for a bedside base unit monitor to transfer data to physicians. Its FDA clearance was the No. 1 most popular article on DAIC in October.

Feature | November 03, 2017 | Dave Fornell

November 3, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional...

VitalConnect Raises $38 Million in Series C Equity Financing
News | Wearable Sensors | November 03, 2017

November 3, 2017 — VitalConnect Inc. announced the fourth and final Series C closing, bringing the total Series C...

Acist Medical Systems Announces Approval and Launch of Next-Generation FFR System
Technology | FFR Technologies | November 03, 2017

November 3, 2017 — Acist Medical Systems Inc., a Bracco Group Company, announced the global launch of its Acist RXi...

Overlay Init